Analyzing Biotricity (NASDAQ:BTCY) and Stryker (NYSE:SYK)

Biotricity (NASDAQ:BTCY) and Stryker (NYSE:SYK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Biotricity and Stryker, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
Stryker	0	4	15	0	2.79

Stryker has a consensus target price of $427.30, indicating a potential upside of 13.34%. Given Stryker’s stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than Biotricity.

Insider and Institutional Ownership

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 5.9% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Biotricity has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Biotricity and Stryker’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Stryker	13.25%	23.58%	11.37%

Valuation and Earnings

This table compares Biotricity and Stryker”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	1.07	-$14.09 million	($1.08)	-0.48
Stryker	$23.22 billion	6.20	$2.99 billion	$7.40	50.95

Stryker has higher revenue and earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Biotricity on 12 of the 14 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.